Ontology highlight
ABSTRACT: Background
Small intestinal bacterial overgrowth (SIBO) is a heterogeneous syndrome, characterised by an increased number and/or abnormal type of bacteria in the small bowel. Over the past decades, rifaximin has gained popularity for this indication despite its use is not evidence based.Aim
To perform a systematic review and meta-analysis to summarise evidence about the efficacy and safety of rifaximin to eradicate SIBO in adult patients.Methods
MEDLINE, EMBASE, CCRCT, Scopus and Web of Science were searched from inception to March 16, 2015 for RCTs and observational studies. Furthermore, abstract books of major European, American and Asian gastroenterological meetings were also examined.Results
Thirty-two studies involving 1331 patients were included. The o
SUBMITTER: Gatta L
PROVIDER: S-EPMC5299503 | biostudies-literature | 2017 Mar
REPOSITORIES: biostudies-literature